What are the Outcomes of Medication Assisted Treatment (MAT)?
--80.avif)
Understanding Medication Assisted Treatment
Before diving into the outcomes of MAT (Medication Assisted Treatment), it is essential to understand what the treatment entails.
Definition of MAT
Medication-assisted treatment (MAT) is an evidence-based treatment that combines medication, social support services, and counseling, to address substance use disorders, particularly opioid use disorder (OUD). The treatment helps manage physical dependence, reduce cravings, prevent relapse, and normalize body functions over time.
MAT is not a new approach, having evolved since the 1950s when methadone was first used for heroin addiction. Today, it is recognized by the Substance Abuse and Mental Health Services Administration (SAMHSA) as a successful treatment for substance use disorders.
For more historical context on MAT, refer to our article on when medication assisted treatment began.
Role of Counseling in MAT
Counseling plays a critical role in MAT, working alongside medication to provide a comprehensive approach to treatment. It helps patients return to productive lives within their families, jobs, and communities by addressing the social and behavioral aspects of addiction.
Through counseling, patients learn to manage their addiction, cope with stress, and build positive relationships. They also acquire skills to avoid situations that could lead to relapse. This combination of medication and therapy has been shown to successfully treat substance use disorders and for some, can help sustain recovery [3].
The ultimate goal of treating substance use disorders is full recovery, defined as the ability to lead a self-directed life. This treatment approach also lowers the risk of contracting HIV or hepatitis C by reducing the potential for relapse.
For further insights on the difference between MAT and other treatment approaches, explore our article on the difference between MAT and OTP as well as the difference between MAT and SUD.
-_1-80.avif)
FDA-Approved Medications for Opioid Use Disorder
Medication Assisted Treatment (MAT) offers hope to individuals struggling with addiction, particularly those battling Opioid Use Disorder (OUD). The Food and Drug Administration (FDA) has approved three medications to treat OUD: methadone, buprenorphine, and naltrexone. These medications are designed to manage cravings and reduce withdrawal symptoms, allowing individuals to actively work on their recovery Behavioral Health Group.
Methadone
Methadone, a long-acting full opioid agonist, is one of the oldest and most trusted medications used in MAT. It was approved for opioid addiction treatment in 1947, and the first MAT program was established in 1971 with methadone maintenance treatment (MMT) Addiction Center.
Methadone works by relieving physiological opioid cravings and normalizing the body's functioning impaired by illicit opioids. It also diminishes the euphoric effects of other opioids, allowing individuals to transition away from substance misuse safely and effectively. Methadone is administered in highly regulated opioid treatment programs (OTPs) and is safe and effective when taken as prescribed Behavioral Health Group.
Buprenorphine
Buprenorphine, a partial opioid agonist, was approved by the FDA for the treatment of opioid use disorders in 2002 Addiction Center. Also known as Suboxone® or Subutex, buprenorphine can reduce cravings and withdrawal symptoms without inducing the dramatic highs and lows of illicit drug abuse. It is regarded as effective for less advanced substance use disorders and is typically provided in physician office practices and OTPs Behavioral Health Group.
Naltrexone
Naltrexone, an opioid antagonist, offers a different approach to OUD treatment. Unlike methadone and buprenorphine, which work by acting on the same targets in the brain as other opioids, naltrexone works by blocking the activation of opioid receptors. This decreases cravings and prevents opioids from producing a "high" Behavioral Health Group.
Naltrexone is available in tablet form for daily oral intake, but it is often given as a long-acting injectable. This makes it a good option for patients who struggle with taking medications regularly Addiction Center.
Each of these medications offers unique benefits, and the choice of medication can be tailored to the individual's specific needs and circumstances. For more information on the difference between MAT and SUD, or the difference between MAT and OTP, visit the linked articles. As always, it's important to consult with a healthcare provider to determine the most appropriate treatment approach.
-_2-80.avif)
Benefits of Medication Assisted Treatment
Medication Assisted Treatment (MAT) is a comprehensive approach that combines medication, counseling, and behavioral therapies for treating substance use disorders, especially opioid use disorders. Understanding the benefits of MAT can help those struggling with addiction to make an informed decision about their treatment options.
Managing Cravings and Withdrawal Symptoms
One of the significant benefits of MAT is its effectiveness in managing withdrawal symptoms and reducing cravings associated with substance use disorders. Medications used in MAT work on brain chemistry to alleviate cravings, block the euphoric effects of opioids, and normalize body functions over time. This helps individuals manage their dependency, reducing the risk of relapse.
According to Behavioral Health Group, MAT allows patients to manage their physical dependence effectively, enabling them to return to productive lives within their families, jobs, and communities. This is a crucial aspect of treatment, as it helps individuals in their recovery journey, making the process less daunting and more manageable.
Comprehensive Approach to Treatment
MAT provides a comprehensive approach to treatment. It combines medication, counseling, and behavioral therapies, offering a well-rounded strategy for tackling substance use disorders. This approach addresses both the physical and psychological aspects of addiction, making it an effective treatment option.
Research shows that a combination of medication and therapy can successfully treat substance use disorders, and for some people, medication can help sustain recovery [3]. This comprehensive approach ensures that all aspects of the individual's addiction are addressed, increasing the chances of long-term recovery.
Furthermore, the use of medications such as Methadone, Buprenorphine, and Naltrexone in MAT has been shown to reduce opioid use, opioid use disorder-related symptoms, infectious disease transmission risk, and criminal behavior associated with drug use [5]. These outcomes reinforce the effectiveness of MAT in treating substance use disorders, making it a viable option for those seeking recovery.
By understanding the benefits of MAT, individuals can make an informed decision about their treatment options. For more information on when medication assisted treatment begins and the difference between MAT and OTP, you can explore our other articles on this topic.
Effectiveness of MAT in Substance Use Disorders
Medication Assisted Treatment (MAT) has shown promising results in the treatment of substance use disorders, specifically opioid use disorder. The significant outcomes of MAT include the reduction in opioid use and lowering the risk of overdose.
Reduction in Opioid Use
Research by the National Institute on Drug Abuse has demonstrated that medications like Methadone, Buprenorphine, and Naltrexone effectively reduce opioid use and opioid use disorder-related symptoms. Furthermore, these medications also aid in reducing the risk of infectious disease transmission and criminal behavior associated with drug use.
Methadone, used since 1947, has proven to be efficacious in reducing opioid use, with patients on Methadone having 33% fewer opioid-positive drug tests. Similarly, Buprenorphine, when given at a sufficiently high dose (generally 16 mg per day or more), has been effective in treating opioid use disorders. Lastly, extended-release injectable Naltrexone (XR-NTX) has shown significant results in increasing opioid abstinence.
Lower Risk of Overdose
Beyond reducing opioid use, the Medication Assisted Treatment (MAT) approach also significantly lowers the risk of overdose. According to NCBI Bookshelf, long-term retention on medication for opioid use disorder is associated with improved outcomes and saved lives.
The same source also pointed out that treatment with methadone or buprenorphine is associated with a 50% reduction in mortality among people with opioid use disorder. This clearly indicates the potential of MAT in saving lives and reducing the societal and personal costs associated with opioid use disorders.
Underlining the effectiveness of this treatment approach, the success of MAT is largely dependent on adherence and retention in the program. It is critical to remember that the journey to recovery from substance use disorders is a process that requires commitment, consistency, and comprehensive care. For a more in-depth understanding of the MAT journey, refer to our articles on when medication assisted treatment begin and the difference between mat and sud.
Comparative Analysis of MAT Medications
An essential part of understanding the outcomes of MAT is comparing the various FDA-approved medications used in the treatment. In this section, we will provide a comparative analysis of methadone, buprenorphine, and naltrexone.
Methadone vs. Buprenorphine
Both methadone and buprenorphine have proven their effectiveness in reducing opioid use. Studies have found no significant differences in opioid-positive drug tests or self-reported heroin use when treated with either methadone or buprenorphine at medium-to-high doses.
Methadone, used since 1947, has shown effectiveness in not only reducing opioid use but also in associated reduction of infectious diseases and crime. It has been found that patients on methadone had 33% fewer opioid-positive drug tests and were 4.44 times more likely to stay in treatment compared to controls [5]. Methadone is often referred to as the gold standard in MAT and can be started at any stage of withdrawal.
On the other hand, buprenorphine, when given at a sufficiently high dose (generally 16 mg per day or more), has been effective in treating opioid use disorders. Patients on doses of buprenorphine of 16 mg per day or more were 1.82 times more likely to stay in treatment than placebo-treated patients [5]. Buprenorphine also serves as an effective tool in reducing cravings, withdrawal, and stress reactivity, and competitively blocks or reduces the reinforcing effects of other opioids.
Naltrexone Effectiveness
Naltrexone, particularly in the extended-release intramuscular injection form (XR-NTX), has shown effectiveness in treating opioid use disorder. A study showed that XR-NTX significantly increased opioid abstinence, with the XR-NTX group having 90% confirmed abstinent weeks compared to 35% in the placebo group [5]. Naltrexone also has been shown to reduce relapse and increase the quality of life. However, it's important to note that individuals must be opioid-free for 7-14 days before initiation of naltrexone.
In summary, methadone, buprenorphine, and naltrexone each have their unique benefits and effectiveness in treating opioid use disorder. It's important to have a detailed discussion with healthcare providers to understand the best course of medication-assisted treatment suitable for individual needs.
Adherence and Retention in MAT Programs
A crucial aspect of understanding the outcomes of MAT (Medication-Assisted Treatment) is examining the role of adherence and retention in these programs.
Importance of Adherence
Adherence to medication is a key indicator in the efficacy and harm reduction of MAT programs. According to a study cited in the Journal of Addictions Nursing, methadone (considered the gold standard in MAT) and buprenorphine have high rates of success, with as much as 60% of individuals remaining opioid-free while on these treatments. However, these positive outcomes are heavily reliant on the patient's adherence to the prescribed medication regimen.
Patients who adhere to their MAT program tend to experience a reduction in opioid use, opioid use disorder-related symptoms, and a lower risk of overdose. These outcomes highlight the critical role that adherence plays in enhancing the effectiveness of MAT and the overall recovery process.
For more information about the importance of adherence in MAT, explore our article on when medication assisted treatment begin.
Motivators for Opioid-Free Life
Identifying and understanding the motivators that drive individuals to remain opioid-free is essential in improving adherence and retention in MAT programs. According to the Journal of Addictions Nursing, research into these motivations is required, and the implementation of external rewards or punitive measures may enhance retention in MAT programs.
Personal motivations can vary widely among individuals and may include the desire to improve health, mend relationships, or increase employment opportunities. Understanding these motivators can help healthcare providers design tailored treatment plans that address individual needs and increase the likelihood of successful recovery.
To learn more about the recovery process and the role of personal motivators in achieving an opioid-free life, check out our article on the difference between mat and sud.
In conclusion, adherence to the prescribed medication regimen and personal motivations to lead an opioid-free life play a significant role in determining the outcomes of MAT. By focusing on these aspects, healthcare providers can enhance the effectiveness of MAT programs and help individuals on their path to recovery.
References
[1]: https://www.azahcccs.gov/Members/BehavioralHealthServices/OpioidUseDisorderAndTreatment/MAT.html
[2]: https://newchoicestc.com/blog/medication-assisted-treatment-pros-and-cons-of-mat-for-recovery-nc/
[3]: https://www.samhsa.gov/medications-substance-use-disorders
[4]: https://www.bhgrecovery.com/blog/medications-used-in-mat
[6]: https://journals.lww.com/jan/fulltext/2023/10000/acomparisonofmedicationassisted_treatment.15.aspx
